HER2 Status in Solid Tumors: [68Ga]Ga-ABY-025 PET Study

We are investigating a new PET imaging method to measure HER2 status in patients with low HER2 breast cancer. This study aims to see if it can help better identify tumor characteristics and improve treatment planning.

>2 years≤5 visitsEfficacy phase (II)No PlaceboStandard MedicinesInjectionGastroenterologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Gallium (68ga) Edotreotide
Gallium-68 edotreotide is a radiolabeled tracer used in PET scans to locate neuroendocrine tumors that have somatostatin receptors.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Karolinska University Hospital
Medical Radiation Physics and Nuclear Medicine
Huddinge, Sweden
Sponsor: Karolinska University Hospital
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.